Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 19, 2026 06:30 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results

ZELSUVMI™ net product revenue grew 28% Quarter over Quarter to $9.1 million, bringing total ZELSUVMI net product revenue to $16.2 million, for the period from the launch in July 2025 through December...
March 12, 2026 08:30 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics to Present at 38th Annual ROTH Conference

DURHAM, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet...
March 09, 2026 08:30 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on March 19, 2026

DURHAM, N.C., March 09, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet...
February 23, 2026 08:00 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference

DURHAM, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet...
January 13, 2026 08:30 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics Secures Up to $50 Million Senior Secured Term Loan Facility from Horizon Technology Finance

DURHAM, N.C., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet...
January 05, 2026 07:30 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics Acquires Xeglyze® (abametapir) Topical Treatment for Head Lice

Acquisition adds complementary asset to the Pelthos commercial portfolioXeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in...
December 23, 2025 17:57 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics Expands Board of Directors with the Appointment of Andrew Einhorn

DURHAM, N.C., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet...
December 04, 2025 07:00 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics Signs Major Pharmacy Benefit Manager Agreement Expanding Patient Access to ZELSUVMI™ (berdazimer) Topical Gel, 10.3%

ZELSUVMI is the first and only FDA-approved at-home treatment for molluscum contagiosum, a highly contagious viral skin condition affecting an estimated 16.7 million people, with up to 6 million new...
December 02, 2025 08:00 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference

DURHAM, N.C., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet...
November 13, 2025 06:45 ET | Source: Pelthos Therapeutics, Inc.

Pelthos Therapeutics Announces Third Quarter Fiscal 2025 Financial Results

Conference call scheduled for November 13, 2025 at 8:00am ET Commercial launch of ZELSUVMI, the first FDA-approved at-home molluscum contagiosum treatment, exceeded expectations and generated $7.1...